H.C. Wainwright analyst Ed Arce lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $60 from $63 and keeps a Buy rating on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback